Marshall Wace
GLUE icon

Marshall Wace’s Monte Rosa Therapeutics GLUE Stock Holding History

Marshall Wace’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.6M Buy
1,593,600
+160,448
+11% +$3.03M 0.03% 470
2026
Q1 		$23.6M Buy
1,433,152
+1,034,262
+259% +$19.8M 0.02% 644
2025
Q4 		$6.25M Sell
398,890
-503,944
-56% -$6.79M 0.01% 1059
2025
Q3 		$6.69M Buy
902,834
+456,754
+102% +$2.42M 0.01% 1082
2025
Q2 		$2.01M Buy
446,080
+74,342
+20% +$332K ﹤0.01% 1564
2025
Q1 		$1.72M Sell
371,738
-127,754
-26% -$783K ﹤0.01% 1534
2024
Q4 		$3.47M Buy
499,492
+325,643
+187% +$2.44M ﹤0.01% 1223
2024
Q3 		$921K Buy
+173,849
New +$877K ﹤0.01% 1681

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace's GLUE Position: Q2 2026 in Review

Marshall Wace increased its Monte Rosa Therapeutics (GLUE) stake by 11% in Q2 2026, buying an estimated $3.03M and bringing the position to 1,593,600 shares worth $38.6M. The position accounts for 0.03% of the portfolio, ranked #470.

Marshall Wace first reported a position in GLUE in Q3 2024 and has held it in 8 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Marshall Wace held 1,593,600 shares of Monte Rosa Therapeutics worth $38.6M as of Q2 2026.
  • Marshall Wace bought 160,448 Monte Rosa Therapeutics shares in Q2 2026, an estimated $3.03M.
  • Monte Rosa Therapeutics made up 0.03% of Marshall Wace's portfolio in Q2 2026, its #470 holding.
  • Marshall Wace first reported a position in Monte Rosa Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.